Warticon (Podophyllotoxin)

O que é Warticon?

Warticon (podophyllotoxin 0.15% creme) is a receita médica topical antimitotic medicamento used to treat external genital and perianal warts (condylomata acuminata) caused by the human papillomavirus (HPV). It belongs to the same therapeutic class as Condyline (podophyllotoxin 0.5% solution), differing in its creme formulation and concentration.

Podophyllotoxin, the active ingredient, is a purified plant-derived cytotoxic agent that works by destroying the rapidly dividing cells of HPV-induced warts. Warticon creme is designed for paciente self-application as part of a structured tratamento cycle.

Como funciona Warticon work?

Podophyllotoxin’s mechanism of action is well characterised as an antimitotic agent:

• Tubulin binding: Podophyllotoxin binds to the protein tubulin, specifically at the colchicine-binding site on the beta-tubulin subunit.
• Microtubule disruption: This binding prevents the polymerisation of tubulin into microtubules, which form the mitotic spindle — the cellular machinery essential for chromosome separation during cell division.
• Mitotic arrest: Without a functional spindle, dividing cells are arrested in the G2/M phase of the cell cycle (just before or during division), unable to complete mitosis.
• Cell necrosis: Cells arrested in mitosis undergo necrosis (death), leading to progressive destruction of the wart tissue over the tratamento cycles.

The creme formulation of Warticon differs from the solution (Condyline) in that the vehicle (creme base) allows the active ingredient to remain at the site of application for longer and may penetrate wart tissue in a more controlled manner, potentially reducing the risk of spreading to surrounding healthy skin compared to a liquid solution.

Para quem é Warticon for?

Warticon creme is suitable for adults with confirmed or clinically assessed external genital and perianal warts who are able to identify the wart tissue clearly and apply the creme accurately.

Particularly appropriate when:

• Warts are located in areas where creme application is easier to control than a liquid solution (e.g., moist perigenital areas)
• The paciente finds the creme formulation easier to apply than a solution applicator
• The médico has assessed that a creme formulation is preferable based on wart characteristics

Warticon is NOT suitable for:

• Pregnant women: Contraindicated due to teratogenic risk
• Internal warts: The creme should not be applied inside the vagina, urethra, or rectum
• Children under 18: Safety not established for this indication
• Large wart areas: More than 4 cm² of total wart surface, or more than 50 separate warts — a médico should assess suitability
• Immunocompromised pacientes: May be less effective and can cause more severe local reactions — specialist input is advisable

Dosagem and Application

Treatment schedule: Apply the creme to each wart twice daily (morning and evening) for 3 consecutive days. Then stop for 4 days. This completes one tratamento cycle. Repeat for up to 4 cycles if needed.

Phase	Days	Action
Treatment	Days 1, 2, 3	Apply creme twice daily to warts only
Rest	Days 4, 5, 6, 7	No tratamento
Repeat	From Day 8	Up to 3 more cycles

Application instructions:

1. Clean and dry the tratamento area before application.
2. Apply a small amount of creme precisely to each wart surface using the finger or applicator provided. Avoid healthy surrounding skin.
3. Allow the creme to dry and absorb before dressing.
4. Wash hands thoroughly after application.
5. Avoid sexual intercourse while the creme is on the skin.
6. Do not occlude the area with airtight dressings.

Maximum per application: No more than 0.5 mL of creme (approximately a 10 cm² area of wart surface) per session.

Efeitos secundários

Local skin reactions are expected and indicate the medicamento is working on wart tissue. Severity depends on the amount applied and individual sensitivity.

Very common efeito secundários

• Burning, stinging, or pain at the tratamento site
• Redness (erythema) of wart tissue
• Itching at the application site
• Erosion or superficial ulceration of wart tissue

Efeitos secundários comuns

• Inflammation of surrounding skin (if the creme contacts healthy tissue)
• Tenderness or soreness

Menos comuns efeito secundários

• Blistering at or near the tratamento site
• Pigmentation changes (may be persistent)
• Drying or scaling of treated area

If severe pain, extensive inflammation, or open sores develop, stop tratamento and consult a médico. Treatment can be restarted when the reaction has subsided.

Systemic effects

Systemic absorption from topical application at recommended doses is minimal. However, if the creme is used on excessively large areas or more frequently than recommended, systemic toxicity (nausea, vomiting, neurological effects) may occur. Adhere strictly to prescribed amounts.

Warticon vs alternativas wart tratamentos

Treatment	Formulation	Concentration	Mechanism	Treatment Cycle
Warticon	Cream	0.15% podophyllotoxin	Antimitotic	3 on / 4 off, up to 4 weeks
Condyline	Solution	0.5% podophyllotoxin	Antimitotic	3 on / 4 off, up to 4 weeks
Aldara	Cream	5% imiquimod	Immune stimulation	3×/week, up to 16 weeks
Cryotherapy	Liquid nitrogen	N/A	Physical destruction	Clinic-based

Warticon vs Condyline: Both are podophyllotoxin preparations with equivalent efficacy in clinical studies. The creme (Warticon) may be preferred for moist mucosal surfaces and areas where precise application of a solution is difficult, while the solution (Condyline) may be preferred for keratinised skin or drier surfaces.

Warticon vs Aldara: Podophyllotoxin (Warticon) works by direct tissue destruction, while imiquimod (Aldara) stimulates the immune system. Podophyllotoxin is generally faster-acting, while imiquimod may have lower recurrence rates due to its immunostimulatory effect. Clinical selection depends on individual assessment by a médico.

Como aceder a Warticon online na Europa

Warticon is a medicamento sujeito a receita médica (POM) in all estados-membros da UE. It cannot legally be dispensed without a valid receita médica from a licensed medical professional.

Prescrivia operates as a technology intermediary: we do not prescribe medicamentos, employ médicos, or sell medicamentos. Our platform connects pacientes with independent EU-registered médicos who can conduct confidential online health assessments.

The process:

1. Complete uma avaliação de saúde: Describe the warts — their size, number, location, and duration — along with your sexual health history and any previous wart tratamentos.
2. Avaliação médica: An independent EU-registered médico reviews your assessment. If Warticon creme is clinically appropriate, they may issue a receita médica.
3. Dispensa na farmácia: The receita médica is sent to a licensed EU farmácia partner for dispensing and direct delivery.

Important: A Prescrivia não garante that a receita médica will be issued. All prescribing decisions are made independently by qualified medical professionals.

Informação de segurança importante

Não utilize Warticon if you:

• Are pregnant or trying to become pregnant
• Are breastfeeding
• Are under 18 years of age
• Are allergic to podophyllotoxin or any ingredient in the creme
• Have open, inflamed, or bleeding skin in the intended tratamento area

Informe o seu médico if you:

• Are immunocompromised (including HIV-positive or on immunosuppressant tratamento)
• Have previously used any other wart tratamento (including cryotherapy or Aldara)
• Are uncertain whether your lesions are genital warts — other conditions including vulval intraepithelial neoplasia (VIN), molluscum contagiosum, and skin cancers can resemble genital warts and must be excluded

Latex contraception: Podophyllotoxin creme may affect latex condoms and diaphragms. Avoid unprotected sexual contact during tratamento.

HPV and recurrence: Treating visible warts removes the physical lesions but does not eliminate the underlying HPV infection. Warts may recur after successful tratamento. The virus can be transmitted to sexual partners even when no visible warts are present.

Fontes

Medical information on this page is based on the following sources:

• Agência Europeia de Medicamentos (EMA). Podophyllotoxin — Summary of Product Characteristics. Available at: ema.europa.eu
• Organização Mundial da Saúde (WHO). Human papillomavirus (HPV) and cervical cancer — Fact sheet. who.int
• Lacey CJ, et al. 2012 European guideline for the management of anogenital warts. Journal of the European Academy of Dermatology and Venereology. 2013;27(3):e28–35.

This content is reviewed periodically to reflect updated clinical guidance. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.